Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
About this trial
This is an interventional treatment trial for Schizophrenia
Eligibility Criteria
Key Inclusion Criteria: At least 18 years of age Have one of the following clinical diagnoses: schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder Have a clinical diagnosis of neuroleptic-induced TD Medication(s) for schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder and other protocol-allowed concurrent medications must be at a stable dose and expected to remain stable during the study Participants must be outpatients and have a stable psychiatric status Key Exclusion Criteria: Have comorbid abnormal involuntary movement(s) (for example, Parkinsonism, akathisia) that is more prominent than TD Have an active, clinically significant unstable medical condition in the judgement of the investigator, or have any laboratory value outside the normal range that is considered by the investigator to be clinically significant at the screening visit
Sites / Locations
- Neurocrine Clinical SiteRecruiting
- Neurocrine Clinical SiteRecruiting
- Neurocrine Clinical SiteRecruiting
- Neurocrine Clinical SiteRecruiting
- Neurocrine Clinical SiteRecruiting
Arms of the Study
Arm 1
Experimental
Valbenazine
Valbenazine administered once daily for 24 weeks.